Active, not recruitingNot applicableNCT05703269
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wake Forest University Health Sciences
- Principal Investigator
- Glenn Lesser, MDWake Forest University Health Sciences
- Intervention
- single fraction stereotactic radiosurgery (SSRS)(radiation)
- Enrollment
- 58 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- Crossroads Cancer Center, Effingham, Illinois, United States
- HSHS Saint Elizabeth's Hospital, O'Fallon, Illinois, United States
- OSF Saint Francis Medical Center, Peoria, Illinois, United States
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor, Michigan, United States
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan, United States
- Genesys Hurley Cancer Institute, Flint, Michigan, United States
- Trinity Health Saint Mary Mercy Livonia Hospital, Livonia, Michigan, United States
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti, Michigan, United States
- Mercy Hospital Springfield, Springfield, Missouri, United States
- Mercy Hospital South, St Louis, Missouri, United States
- Overlook Medical Center, Summit, New Jersey, United States
- Lovelace Medical Center-Saint Joseph Square, Albuquerque, New Mexico, United States
- Lovelace Radiation Oncology, Albuquerque, New Mexico, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05703269 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
- RECRUITINGPHASE2NCT06946797A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)Bristol-Myers Squibb
- RECRUITINGPHASE2NCT07086456Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerSun Yat-sen University
- RECRUITINGNANCT07086300Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLCKong Fanming
- RECRUITINGPHASE2NCT06620835Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibGroupe Francais De Pneumo-Cancerologie
- RECRUITINGPHASE1, PHASE2NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsTango Therapeutics, Inc.
- RECRUITINGPHASE3NCT07050043Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCDr Arvindran A/L Alaga
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →